News Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:41:23 2025-12-16 pm EST			5-day change	1st Jan Change
1,046.03 ^USD	-1.52%		+6.11%	+35.00%

06:17am	Daiwa Upgrades Eli Lilly and Co. to Buy From Neutral, Adjusts Price Target to $1,230 From $940	MT
05:34am	Analyst recommendations: Accenture, Albemarle, Eli Lilly, Gitlab, Okta…

Lilly to participate in J.P. Morgan Healthcare Conference	10:01am	PR
Daiwa Upgrades Eli Lilly and Co. to Buy From Neutral, Adjusts Price Target to $1,230 From $940	06:17am	MT
Analyst recommendations: Accenture, Albemarle, Eli Lilly, Gitlab, Okta…	05:34am
Health Care Up on Defensive Bias -- Health Care Roundup	Dec. 15	DJ
Sector Update: Health Care Stocks Gain Late Afternoon	Dec. 15	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	Dec. 15	MT
Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says	Dec. 15	MT
US FDA grants priority voucher to J&J's blood cancer treatment	Dec. 15	RE
Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026	Dec. 15	MT
Amphastar Pharmaceuticals Says FDA Approved Teriparatide Injection as Osteoporosis Treatment	Dec. 15	MT
Amphastar announces FDA approval for teriparatide injection	Dec. 15	RE
Health Care Flat on Defensive Bias - Health Care Roundup	Dec. 12	DJ
Sector Update: Health Care Stocks Advance Late Afternoon	Dec. 12	MT
SOFTS-Raw sugar closes up 1.7% on bullish technical signals; robusta coffee finishes at close to four-month low	Dec. 12	RE
Sector Update: Health Care Stocks Edge Higher Friday Afternoon	Dec. 12	MT
Sector Update: Health Care	Dec. 12	MT
Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo? (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer	Dec. 12	CI
Eli Lilly Inluriyo Shows 38% Risk Reduction, Extends Median Survival in Advanced Breast Cancer	Dec. 12	MT
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer	Dec. 12	PR
SOFTS-Raw sugar gains on bullish technical signals; robusta coffee slides	Dec. 12	RE
Ozempic launches in India at $24 a week as Novo targets booming market	Dec. 12	RE
Rate Cuts Can't Buy Confidence	Dec. 12
EU committee backs extending use of Lilly's diabetes drug for children aged 10 and above	Dec. 12	RE
FDA reportedly seeks to expedite review of Lilly's weight loss pill - Reuters	Dec. 12	FW
Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026	Dec. 12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound

December 01, 2025 at 10:39 am EST

Is it back to square one for Eli Lilly?

August 07, 2025 at 11:20 am EDT